1Biondi-Zoccai GG, Sangiorgi GM, Antoniucci D, et al.Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study[J].Int J Cardiol, 2007, (117):349-354.
2Gao RL, Xu B, Lu SZ, et al.Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the “Real World”-Clinical and angiographic results from the China CYPHER Select registry[J].Int J Cardiol, 2008, 125(3):339-346.
3Ahmed WH, Zambahari R, AI-Rashdan I, et al.One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I)[J].Int J Cardiol, 2008, 21(6):512-518.
5Han Y, Jing Q, Chen X, et al.Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents[J].Catheter Cardiovasc Interv, 2008, 72(2):177-183.
2Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, 109: 1244-1249.
3Tanabe K, Hoye A, Lemos PA, el al. Restonosis rates following bifurcation stenting with sirolimus-eluting stents for De Novo narrowings. Am J Cardiol, 2004,91 : 115-118.
4Smith SC, Dove JT, Kennedy JW, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PICA guidelines-executive summary). A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise, the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coil Cardiol, 2001,37:2215-2239.
5Ong AT, Aoki J, Mcfadden EP, et al. Classitication and current treatment options of in-stent restenoses. Present status and future perspectives. Herz, 2004,29: 187-194.
6Leon MB, T eirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenoses after stenting. N Eng J Med, 2001,344:250-256.
7Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenoses in a native coronary artery. N Eng J Med, 2003,349: 1315-1323.
8Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirlimus-eluting stents compared with conventional bare stent implantation in the real world: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (REASERCH) Registry.Circulation, 2004,109; 190-195.
9Thomas TS, Williams DO, Most AS. Efficacy of coronary, angioplasty of bifurcation lesions : Immediate and late outcome. Circulation, 1988,78 :254-632.
